by admin | May 1, 2026
The definition of response and inadequate response to topical corticosteroid treatment in atopic dermatitis and related skin inflammatory diseases: A GA2LEN ADCARE statement paperZuberbier, T., Abuzakouk, M., Angelova Fischer, I., Arruda, L. K., Augustin, M., Beck,...
by | May 1, 2026
The definition of response and inadequate response to topical corticosteroid treatment in atopic dermatitis and related skin inflammatory diseases: A GA2LEN ADCARE statement paperZuberbier, T., Abuzakouk, M., Angelova Fischer, I., Arruda, L. K., Augustin, M., Beck,...
by | May 1, 2026
The definition of response and inadequate response to topical corticosteroid treatment in atopic dermatitis and related skin inflammatory diseases: A GA 2LEN ADCARE statement paper.Zuberbier, T., Abuzakouk, M., Angelova Fischer, I., Arruda, L. K., Augustin, M., Beck,...
by | Apr 30, 2026
Evaluation of a Therapeutic Drug Monitoring Strategy for Adalimumab in Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic StudyBADBIR Study Group, the PSORT Consortium & BSTOP study group, 30 Apr 2026, In: Clinical and Translational Science. 19, 5, p....
by | Apr 30, 2026
Serious infection risk of certolizumab compared with other systemic therapies in women with psoriasisBright, H. R. B., Smith, C. H., Laws, P., Reynolds, N. J., Hughes, O., Phan, D. B., Lunt, M., Warren, R. B. & Yiu, Z. Z. N., 30 Apr 2026, (E-pub ahead of print)...